COMMUNIQUÉS West-GlobeNewswire

Transactions in connection with share buy-back program
24/03/2026
Company announcement no. 6 - 26 24 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
24/03/2026
Inclusion in U.S. CRSP ® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fund Expands market presence across the [...]
Serina Therapeutics to Present at the 38th Annual Roth Conference
24/03/2026
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
MINES and Associates COO Recognized as 2026 Colorado Titan 100 Recipient
24/03/2026
LITTLETON, Colo., March 24, 2026 (GLOBE NEWSWIRE) -- MINES and Associates (MINES) is proud to announce that its Chief Operating Officer, Myron Unruh, has been named a 2026 Colorado Titan 100 recipient, an honor that [...]
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
24/03/2026
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer [...]
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24/03/2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards
24/03/2026
Phonak Virto R Infinio and Phonak Infinio Ultra Sphere honored for advancing real-world hearing performance through AI innovation STÄFA, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in [...]
Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »
24/03/2026
Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026 . Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. Résultats du premier [...]
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
24/03/2026
Focused on selective acquisitions of high-quality companies in strategic industrial sectors MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge 1 , a strategic [...]
Press release: Availability of the Q1 2026 aide-mémoire
24/03/2026
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026 . Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24/03/2026
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
24/03/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients atteints d’une forme [...]
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
24/03/2026
First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and [...]
Idorsia announces the nomination of three candidates for election to the Board of Directors
24/03/2026
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026 All Board members – current and [...]
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
24/03/2026
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a [...]
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
23/03/2026
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice [...]
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
23/03/2026
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program [...]

Pages